Performance Improvement 2011-2012. Has the Clinical Proteomics Technology for Cancer Program Been Implemented as Intended and What are Its Short-term Outcomes?


This study assessed the extent to which the Clinical Proteomic Technologies for Cancer (CPTC) program was implemented as intended and its short-term effects on the proteomic research community. The program was established to enhance technical abilities to identify and measure proteins accurately and increase reproducibility of proteomic biomarkers in biological systems and to advance proteomics as a reliable, quantitative field that can accelerate discovery and translational research. The program has three interrelated components: the Clinical Proteomic Technology Assessment for Cancer; the Advanced Proteomic Platforms and Computational Sciences; and Proteomic Reagents and Resources Core. This study evaluated processes and short-term outcomes. Data was collected from Clinical Proteomic Technology Assessment for Cancer participants and stakeholders through interviews and on-site visits as well as program reports, publications, and related grant and publication data.

The program achieved significant milestones. Moreover, the program successfully established a collaborative working relationship among the participating institutions and individuals and participating institutions were not in direct competition with one another. Efforts to standardize existing technology were accelerated by the program.

Report Title: An Extended Feasibility Analysis of the Clinical Proteomics Technology for Cancer Initiative
Agency Sponsor: NIH, National Institutes of Health
Federal Contact: Rosanna Ng, 301-496-5367
Performer: Macro International, Inc.
Record ID: 9418 (Report issued December 2, 2009)

View full report


"PerformanceImprovement2011-2012.pdf" (pdf, 701.44Kb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®